GLP-1 medications in Singapore: Ozempic vs Wegovy vs Saxenda

Interest in GLP-1 medications has increased significantly in Singapore, and three names are commonly mentioned: Ozempic, Wegovy, and Saxenda.

While they are often discussed together, these medications are not the same. They differ in how they are approved, how they are used, and who they may be suitable for.

Understanding these differences is important, particularly as Singapore places increasing emphasis on addressing obesity and metabolic health at a population level.

There is a clear public health context behind the rising interest.

Singapore’s National Population Health Survey 2024 found that obesity among residents increased from 10.5% in 2019–2020 to 12.7% in 2023–2024, with the increase more pronounced among young adults.

At a policy level, this aligns with Singapore’s broader shift toward preventive care. Under initiatives such as Healthier SG, the Ministry of Health has emphasised the importance of managing chronic conditions early, including obesity and metabolic risk.

Health Minister Ong Ye Kung has highlighted that chronic diseases such as diabetes and obesity are long-term challenges for Singapore, requiring sustained lifestyle changes supported by appropriate medical care.

Against this backdrop, more patients are asking about clinically guided options, including GLP-1 medications.

All three medications belong to a class called GLP-1 receptor agonists.

They mimic a natural hormone involved in regulating appetite, digestion, and blood sugar. Because of these shared effects, they are often grouped together in conversations about weight management.

However, the key differences lie in:

• their approved use in Singapore
• dosing frequency
• clinical context

Although Ozempic and Wegovy contain the same active ingredient, they are not interchangeable. They are approved and used differently.

Ozempic is approved in Singapore for adults with type 2 diabetes, as an addition to diet and exercise.

It is administered as a once-weekly injection and is designed to support blood sugar control.

While it is sometimes discussed in the context of weight management, its approved use in Singapore remains for diabetes. Any use outside of this requires careful clinical consideration.

Wegovy is approved in Singapore for weight management in adults who meet specific clinical criteria, such as obesity or being overweight with weight-related conditions.

It is administered as a once-weekly injection and is intended to be used alongside lifestyle and medical support.

Clinical studies have shown that semaglutide-based treatments can support average weight reductions of around 10 to 15 percent in appropriate patients under medical supervision (Wilding et al., 2021).

Saxenda is also approved in Singapore for weight management.

It is administered as a daily injection and may be considered depending on individual response, tolerance, and clinical profile.

For some patients, dosing frequency and how the body responds over time may influence which option is more suitable.

Although these medications share a similar mechanism, the choice between them is not simply about preference.

Doctors typically consider:

• clinical indication (diabetes vs weight management)
• body mass index and overall health profile
• presence of related conditions such as diabetes or cardiovascular risk
• response to treatment over time
• dosing suitability (daily vs weekly)

This reflects a broader shift in healthcare. Rather than focusing on a single treatment, decisions are increasingly based on overall risk profile and long-term health outcomes.

No. GLP-1 medications are prescription treatments that require medical assessment. Not everyone will be suitable for them.

Suitability depends on:

• overall health and medical history
• weight-related health risks
• current medications
• ability to tolerate and adhere to treatment

There may also be side effects, particularly in the early stages, which need to be monitored.

Local reporting has also highlighted risks associated with obtaining such medications from unregulated sources, including unknown ingredients and misleading claims.

From a clinical standpoint, the focus is not on the medication itself, but on whether it is appropriate for the individual.

“GLP-1 medications can be a useful option for some patients, but they are not a starting point on their own. What matters is understanding the patient’s overall health, including metabolic factors, lifestyle, and risk profile, before deciding if medication should be part of the plan.”

At the same time, expectations need to be managed.

“Some patients come in expecting a quick solution, but weight management is still a long-term process. Medication, if used, needs to be combined with appropriate lifestyle adjustments and regular follow-up to achieve and maintain results.”

These perspectives reflect how these treatments are typically used in practice, as part of a broader, structured approach rather than a standalone solution.

With increasing awareness, it is common for patients to ask about specific medications by name. As clinical practice reflects, the more appropriate starting point is understanding your health profile and what options may be suitable.

A structured, doctor-guided approach helps to:

• determine whether medication is appropriate
• select the most suitable option if needed
• monitor progress and adjust treatment
• support more consistent outcomes over time

This approach is aligned with Singapore’s broader healthcare direction, which emphasises preventive care and long-term health management.

For those exploring GLP-1 medications, starting with a proper assessment provides clearer direction.

At HMI Medical Centre, weight management begins with a Weight & Metabolic Health Assessment. This allows doctors to review your health profile and determine whether a structured care plan, which may include medication, is appropriate.

If you would like to better understand your options, speaking with the healthcare team can help you make a more informed decision.

Ozempic, Wegovy, and Saxenda are often discussed together, but they are not interchangeable. They differ in their approved use, dosing, and clinical role. The right approach is not choosing a medication upfront, but understanding what is appropriate for your individual health profile.

1. Ministry of Health Singapore (2024). National Population Health Survey 2024.https://www.moh.gov.sg/newsroom/national-population-health-survey-2024-shows-singaporeans-are-adopting-healthier-lifestyles---but-rising-obesity-is-a-concern
2. Wilding, J.P.H. et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine.https://www.nejm.org/doi/full/10.1056/NEJMoa2032183